3-苄氧基-环丁基胺置于盐酸,Palladium 10% On Activated Carbon,氢气体系中,用 甲醇 作为反应溶剂,化学反应 6.0H,以ca. 35 G的收率获得产物3-氨基环丁醇 参考文献:Potent And Cellularly Active 4-Aminoimidazole Inhibitors Of Cyclin-Dependent Kinase 5/p25 For The Treatment Of Alzheimer's Disease 标题:Potent And Cellularly Active 4-Aminoimidazole Inhibitors Of Cyclin-Dependent Kinase 5/p25 For The Treatment Of Alzheimer's Disease 摘要:Utilizing Structure-Based Drug Design,A 4-Aminoimidazole Heterocyclic Core Was Synthesized As A Replacement For A 2-Aminothiazole Due To Potential Metabolically Mediated Toxicity. The Synthetic Route Utilized Allowed For Ready Synthesis Of 1-Substituted-4-Aminoimidazoles. Sar Exploration Resulted In The Identification Of A Novel Cis-Substituted Cyclobutyl Group That Gave Improved Enzyme And Cellular Potency Against Cdk5/p25 With Up To 30-Fold Selectivity Over Cdk2/cyclin E. (C) 2009 Elsevier Ltd. All Rights Reserved. DOI:10.1016/j.Bmcl.2009.08.019
专利号:US-2023025807-A1 优先权日:2019-10-30 标题:Cd38 inhibitors 发明人:KULKARNI SANTOSH S; LAGU BHARAT; WU XINYUAN 权利人:MITOBRIDGE INC 摘要:The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD + or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).
参考文献:10.1021/ol049416y 摘要:Helal CJ, Kang Z, Lucas JC, Bohall BR. Stereoselective synthesis of cis-1,3-disubstituted cyclobutyl kinase inhibitors. Org Lett. 2004 May 27;6(11):1853–6. doi: 10.1021/ol049416y.